ERBB2 and breast carcinoma: These data demonstrate that MAPK activation in HER2 + breast cancers promotes a switch in cell cycle control from AKT to MAPK that drives resistance to HER2-targeted agents but also enforces a strong and targetable dependence on MEK/ERK signaling.